TELO News and Press, Telomir Pharmaceuticals Inc.

Blend Labs Inc. Class A (BLND) is expected to report $-0.02 for Q4 2025 United Natural Foods Inc. (UNFI) is expected to report $0.51 for Q2 2026 Consumer Portfolio Services Inc. (CPSS) is expected to report $0.23 for Q4 2025 Westrock Coffee Company (WEST) is expected to report $-0.1 f...

GitLab Inc. (GTLB) is expected to report $-0.02 for Q4 2026 Ross Stores Inc. (ROST) is expected to report $1.88 for Q4 2026 Advantage Solutions Inc. (ADV) is expected to report $0.07 for Q4 2025 Hyster-Yale Inc. Class A (HY) is expected to report $-1.2 for Q4 2025 Versant Media Gr...

Interface Inc. (TILE) is expected to report $0.4 for Q4 2025 Evolent Health Inc Class A (EVH) is expected to report $-0.03 for Q4 2025 MercadoLibre Inc. (MELI) is expected to report $11.77 for Q4 2025 Clean Energy Fuels Corp. (CLNE) is expected to report $-0.1 for Q4 2025 Kiniksa ...

2026-02-17 09:35:00 ET Telomir Pharmaceuticals (NASDAQ: TELO) announced new in vitro data showing that Telomir-1 (Telomir-Zn) induced broad tumor cell mortality across biologically distinct subtypes of triple-negative breast cancer, with iron-rescue experiments confirming the effect is ...

Iron-rescue experiments confirm tumor cell mortality is mechanistically driven, not nonspecific cytotoxicity. MIAMI, FL / ACCESS Newswire / February 17, 2026 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a preclinical-stage biotechnology company developing ...

Iamgold Corporation (IAG) is expected to report $0.55 for Q4 2025 Bel Fuse Inc (BELFB) is expected to report $1.44 for Q4 2025 Beta Bionics Inc. (BBNX) is expected to report $-0.42 for Q4 2025 TPG RE Finance Trust Inc. (TRTX) is expected to report $0.25 for Q4 2025 CEVA Inc. (CEVA...

Klaviyo Inc. Series A (KVYO) is expected to report $0.04 for Q4 2025 Diodes Incorporated (DIOD) is expected to report $0.26 for Q4 2025 CRISPR Therapeutics AG (CRSP) is expected to report $-1.15 for Q4 2025 Brighthouse Financial Inc. (BHF) is expected to report $5.19 for Q4 2025 B...

Telomir Pharmaceuticals Inc. (TELO) is expected to report $-0.07 for Q4 2025

2026-02-05 09:15:00 ET Telomir Pharmaceuticals (NASDAQ: TELO) announced new cellular study results showing that Telomir-1, administered as Telomir-Zn, induces a rapid and coordinated redistribution of intracellular metals, simultaneously increasing zinc levels while reducing redox-activ...

Cellular findings show Telomir-Zn modulates intracellular metal balance linked to oxidative stress, mitochondrial dysfunction, DNA methylation instability, and genomic integrity-without relying on cytotoxic mechanisms. MIAMI, FLORIDA / ACCESS Newswire / February 5, 2026 / Telomir Pharmac...